目的 探讨清脑降压胶囊联合左氨氯地平治疗原发性高血压的临床疗效。方法 选取2021年6月—2024年6月深圳市龙华区人民医院收治的116例原发性高血压患者，按随机数字表法分为对照组和治疗组，每组各58例。对照组给予苯磺酸左氨氯地平片口服，2.5 mg/次，1次/d。治疗组在此基础上口服清脑降压胶囊，3粒/次，3次/d。两组疗程均是8周。观察两组临床疗效，比较两组治疗前后诊室血压、相关量表[高血压心身问卷、自测健康评定量表（SRHMS）、杜氏高血压生活质量量表]评分及血清C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、皮质醇（Cor）、醛固酮（ALD）、血管紧张素Ⅱ（AngⅡ）水平。结果 治疗组总有效率是98.28%，显著高于对照组的86.21%（P＜0.05）。治疗后，两组诊室DBP、SBP都低于组内治疗前（P＜0.05）；治疗后，治疗组诊室DBP、SBP都低于对照组（P＜0.05）。治疗后，两组高血压心身问卷评分都显著降低，SRHMS和杜氏高血压生活质量量表评分显著升高（P＜0.05）；治疗后，治疗组高血压心身问卷评分低于对照组，而SRHMS和杜氏高血压生活质量量表评分高于对照组（P＜0.05）。治疗后，两组血清CRP、TNF-α、Cor、ALD和AngⅡ水平都低于同组治疗前（P＜0.05）；治疗后，治疗组CRP、TNF-α、Cor、ALD和AngⅡ水平都低于对照组（P＜0.05）。结论 原发性高血压采用清脑降压胶囊联合左氨氯地平治疗，安全性较好，能有效调节患者机体炎症状态及内分泌激素，促进血压降低及心身症状、总体健康状况和生活质量的改善。

Objective To explore the clinical efficacy of Qingnao Jiangya Capsules combined with levoamlodipine in treatment of primary hypertension. Methods A total of 116 patients with primary hypertension admitted to People’s Hospital of Longhua, Shenzhen from June 2021 to June 2024 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in control group were po administered with Levamlodipine Besilate Tablets, 2.5 mg/time, once daily. Patients in treatment group were po administered with Qingnao Jiangya Capsules on the basis of the control group, 3 grains/time, three times daily. Both groups were treated for 8 weeks. The clinical efficacy of the two groups was observed. The blood pressure of consultation rooms, the scores of relevant scales (Hypertension Psychosomatic questionnaire, SRHMS, Duchenne Hypertension Quality of Life Scale) scores and the levels of CRP, TNF-α, Cor, ALD, and AngⅡ were compared between two groups before and after treatment. Results The total effective rate of the treatment group was 98.28%, significantly higher than that of the control group (86.21%) (P < 0.05). After treatment, DBP and SBP in two groups were lower than before treatment (P < 0.05). After treatment, DBP and SBP in treatment group were lower than those in control group (P < 0.05). After treatment, psychosomatic questionnaire scores were significantly decreased in both groups, but SRHMS scores and Duchenne Hypertension Quality of Life scores were significantly increased (P < 0.05). After treatment, psychosomatic questionnaire scores in the treatment group were lower than those in control group, but SRHMS scores and Duchenne Hypertension Quality of Life scores were higher than those in control group (P < 0.05). After treatment, serum levels of CRP, TNF-α, Cor, ALD, and AngⅡ in two groups were lower than before treatment (P < 0.05). After treatment, the levels of CRP, TNF-α, Cor, ALD, and AngⅡ in treatment group were lower than those in control group (P < 0.05). Conclusion The treatment of primary hypertension with Qingnao Jiangya Capsules combined with levoamlodipine has good safety and can effectively regulate the inflammatory state and endocrine hormones of patients, promote blood pressure reduction, which can improve psychosomatic symptoms, overall health status, and quality of life.

R972

广东省药学会科学研究基金（2023KP09）